Results 1 to 10 of about 274,583 (262)
Cancer Cell, 2022 Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and where we stand on their clinical development, plus the challenges we need to overcome for ...
Schiller, John T +13 more
openaire +2 more sources
Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
Cell Reports, 2021 Summary: An effective HIV-1 vaccine will likely need to elicit broadly neutralizing antibodies (bNAbs). Broad and potent VRC01-class bNAbs have been isolated from multiple infected individuals, suggesting that they could be reproducibly elicited by ...
Emilie Seydoux +13 more
doaj +1 more source
OncoImmunology, 2021 Human microbiota influence the response of malignancies to treatment with immune checkpoint blockade; however, their impact on other forms of immunotherapy is poorly understood.
Duo Yang +12 more
doaj +1 more source
Viruses, 2022 Human T-cell Leukemia virus type-1 (HTLV-1) causes adult T-cell leukemia/lymphoma (ATLL), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and other inflammatory diseases.
Cynthia A. Pise-Masison +1 more
doaj +1 more source
Nature Communications, 2023 HIV vaccine development can be aided by knowledge of correlates of protection. Here the authors identify engagement and reprogramming of tolerogenic CD14+ myeloid cells mediating a spatiotemporal balance of pro- and anti-inflammatory responses, as ...
Massimiliano Bissa +34 more
doaj +1 more source
Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
Nature Communications, 2020 Currently there is neither a vaccine nor an effective treatment strategy available for COVID19. Here, Hurlburt et al. provide the crystal structure of a patient-derived monoclonal antibody neutralizing SARS-CoV-2 via shedding of the S1 subunit and ...
Nicholas K. Hurlburt +9 more
doaj +1 more source
Cervical Cancer-Associated Human Papillomavirus 16 E7 Oncoprotein Inhibits Induction of Anti-Cancer Immunity by a CD4+ T Cell Dependent Mechanism [PDF]
, 2009 Attempts to develop therapeutic vaccines against cervical cancer have been proven difficult. One of the major causes of the failure is due to the use of the wrong mouse models based on transplantable tumours in testing the efficacy of vaccines.
Germain J. Fernando +3 more
core +2 more sources
Primary Care: Clinics in Office Practice, 2011 The term cancer vaccines encompasses 2 different types of vaccines. Prophylactic vaccines block infection by viruses that can alter host DNA and result in cancer. The hepatitis B vaccine and the human papillomavirus vaccines are examples of prophylactic vaccines that can prevent cancer from developing.
openaire +4 more sources
Uptake of three doses of HPV vaccine by primary school girls in Eldoret, Kenya : a prospective cohort study in a malaria endemic setting [PDF]
, 2018 Background: All women are potentially at risk of developing cervical cancer at some point in their life, yet it is avoidable cause of death among women in Sub- Saharan Africa with a world incidence of 530,000 every year.
Kirop, Elijah +8 more
core +3 more sources
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]
, 2018 Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B. +5 more
core +2 more sources